HK1251166A1 - 平滑肌肉瘤的靶向療法 - Google Patents

平滑肌肉瘤的靶向療法

Info

Publication number
HK1251166A1
HK1251166A1 HK18110654.6A HK18110654A HK1251166A1 HK 1251166 A1 HK1251166 A1 HK 1251166A1 HK 18110654 A HK18110654 A HK 18110654A HK 1251166 A1 HK1251166 A1 HK 1251166A1
Authority
HK
Hong Kong
Prior art keywords
leiomyosarcoma
targeted treatment
targeted
treatment
Prior art date
Application number
HK18110654.6A
Other languages
English (en)
Inventor
A Benhadji Karim
Massard Christophe
Soria Jean-Charles
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1251166A1 publication Critical patent/HK1251166A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18110654.6A 2015-04-14 2018-08-20 平滑肌肉瘤的靶向療法 HK1251166A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147104P 2015-04-14 2015-04-14
PCT/US2016/026119 WO2016168014A1 (en) 2015-04-14 2016-04-06 Targeted treatment of leiomyosarcoma

Publications (1)

Publication Number Publication Date
HK1251166A1 true HK1251166A1 (zh) 2019-01-25

Family

ID=55752808

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110654.6A HK1251166A1 (zh) 2015-04-14 2018-08-20 平滑肌肉瘤的靶向療法

Country Status (8)

Country Link
US (1) US10555951B2 (zh)
EP (1) EP3283079B1 (zh)
JP (1) JP6412278B2 (zh)
CN (1) CN107427523B (zh)
ES (1) ES2760462T3 (zh)
HK (1) HK1251166A1 (zh)
TW (1) TWI609687B (zh)
WO (1) WO2016168014A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
ES2898952T3 (es) 2016-04-12 2022-03-09 Lilly Co Eli Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
SG11201810268YA (en) 2016-05-20 2018-12-28 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
EP3506905B1 (en) * 2016-08-31 2024-03-20 Eli Lilly and Company Dosage regimen for the treatment of solid tumors
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
CN110383066B (zh) 2016-12-09 2023-03-31 戴纳立制药公司 化合物、组合物和方法
US11845803B2 (en) 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
JP7233425B2 (ja) * 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196641B1 (pl) 1996-12-23 2008-01-31 Elan Pharm Inc Związki laktamowe i środek farmaceutyczny
JP2002526109A (ja) * 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
CN101583624B (zh) * 2006-09-29 2012-11-21 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物及其用途
JP5560270B2 (ja) * 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP3029070A1 (en) * 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
WO2011060051A1 (en) 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
JO3148B1 (ar) * 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
EP2897938B1 (en) * 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
ES2898952T3 (es) 2016-04-12 2022-03-09 Lilly Co Eli Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario
SG11201810268YA (en) 2016-05-20 2018-12-28 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
EP3506905B1 (en) 2016-08-31 2024-03-20 Eli Lilly and Company Dosage regimen for the treatment of solid tumors
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor

Also Published As

Publication number Publication date
CN107427523A (zh) 2017-12-01
US10555951B2 (en) 2020-02-11
TW201709913A (zh) 2017-03-16
ES2760462T3 (es) 2020-05-14
EP3283079A1 (en) 2018-02-21
JP6412278B2 (ja) 2018-10-24
EP3283079B1 (en) 2019-09-25
US20180104254A1 (en) 2018-04-19
TWI609687B (zh) 2018-01-01
WO2016168014A1 (en) 2016-10-20
JP2018511629A (ja) 2018-04-26
CN107427523B (zh) 2020-08-14

Similar Documents

Publication Publication Date Title
HRP20181692T1 (hr) Liječenje fibroze
IL283258A (en) A preparation for the treatment of hypothyroidism
IL252839A0 (en) Treatment of boils
HK1251166A1 (zh) 平滑肌肉瘤的靶向療法
GB201701673D0 (en) Methods of well treatment
PL3851537T3 (pl) Leczenie hiperbilirubinemii
SG11201609652RA (en) Treatment of polybacterials infections
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
HK1249865B (zh) 疼痛的治療
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201514729D0 (en) Treatment of haemorrhoids
GB201504413D0 (en) Treatment of disease
GB201501800D0 (en) Treatment of medical conditions
GB201511017D0 (en) Method of treatment
GB201513922D0 (en) Treatment of hyperpigmentation
GB201407806D0 (en) Treatment of fibrosis
PT3851537T (pt) Tratamento da hiperbilirrubinemia